Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Globus Medical (GMED)

Globus Medical reports Q4 2025 sales of $823.2 million, up 25.2% from a year earlier

Positive Impact 3 of 5 earnings Written later

Globus Medical said preliminary unaudited sales were about $823.2 million for the fourth quarter of 2025 and about $2.936 billion for full year 2025, up 25.2% and 16.5% on an as-reported basis. The company also set 2026 revenue guidance of $3.18 billion to $3.22 billion and non-GAAP diluted EPS of $4.30 to $4.40, though the figures remain subject to change until final results are released on February 24, 2026.

Key points

  • Q4 2025 sales of approximately $823.2 million, up 25.2% from Q4 2024 on an as-reported basis
  • Q4 2025 base business revenue, excluding Nevro, was $723.3 million, up 10.0%, led by US Spine
  • FY2025 sales of approximately $2.936 billion, up 16.5%; 2026 revenue guidance $3.18 billion to $3.22 billion
  • 2026 non-GAAP diluted EPS guidance of $4.30 to $4.40; final results due February 24, 2026

The filing

CompanyGlobus Medical (GMED)
Form8-K, current report
Filed with the SECJan 7, 2026, 4:32 PM ET
Accession number0001628280-26-001189

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.